vs
Side-by-side financial comparison of Coherus Oncology, Inc. (CHRS) and Velo3D, Inc. (VELO). Click either name above to swap in a different company.
Coherus Oncology, Inc. is the larger business by last-quarter revenue ($12.7M vs $9.4M, roughly 1.4× Velo3D, Inc.). Velo3D, Inc. runs the higher net margin — -231.9% vs -295.3%, a 63.4% gap on every dollar of revenue. On growth, Coherus Oncology, Inc. posted the faster year-over-year revenue change (64.9% vs -25.2%). Over the past eight quarters, Velo3D, Inc.'s revenue compounded faster (-1.8% CAGR vs -47.0%).
Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company focused on developing, manufacturing and commercializing affordable oncology treatments, including FDA-approved biosimilars and novel targeted immuno-oncology therapies. Its core market is North America, serving patients with solid tumors and hematological malignancies to expand access to life-saving cancer care.
Velo3D, Inc. develops and sells advanced end-to-end metal additive manufacturing (3D printing) solutions, comprising industrial-grade printers, specialized processing software, and high-performance metal materials. It primarily serves global aerospace, defense, energy, semiconductor and industrial manufacturing markets, enabling customers to produce complex, high-precision metal parts that are difficult to manufacture with traditional methods.
CHRS vs VELO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $12.7M | $9.4M |
| Net Profit | $-37.6M | $-21.9M |
| Gross Margin | 68.3% | -73.6% |
| Operating Margin | -359.9% | -231.0% |
| Net Margin | -295.3% | -231.9% |
| Revenue YoY | 64.9% | -25.2% |
| Net Profit YoY | 25.7% | -2.9% |
| EPS (diluted) | $-0.34 | $-0.87 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $12.7M | $9.4M | ||
| Q3 25 | $11.6M | $13.6M | ||
| Q2 25 | $10.3M | $13.6M | ||
| Q1 25 | — | $9.3M | ||
| Q4 24 | — | $12.6M | ||
| Q3 24 | — | $8.2M | ||
| Q2 24 | $10.3M | $10.3M | ||
| Q1 24 | — | $9.8M |
| Q4 25 | $-37.6M | $-21.9M | ||
| Q3 25 | $-35.5M | $-11.2M | ||
| Q2 25 | $297.8M | $-13.3M | ||
| Q1 25 | — | $-25.0M | ||
| Q4 24 | — | $-21.3M | ||
| Q3 24 | — | $-21.9M | ||
| Q2 24 | $-12.9M | $935.0K | ||
| Q1 24 | — | $-27.5M |
| Q4 25 | 68.3% | -73.6% | ||
| Q3 25 | 67.8% | 3.2% | ||
| Q2 25 | 66.9% | -11.7% | ||
| Q1 25 | — | 7.5% | ||
| Q4 24 | — | -3.5% | ||
| Q3 24 | — | 49.4% | ||
| Q2 24 | 82.4% | -28.0% | ||
| Q1 24 | — | -28.8% |
| Q4 25 | -359.9% | -231.0% | ||
| Q3 25 | -383.1% | -73.3% | ||
| Q2 25 | -443.6% | -85.4% | ||
| Q1 25 | — | -123.6% | ||
| Q4 24 | — | -167.0% | ||
| Q3 24 | — | -213.8% | ||
| Q2 24 | -384.9% | -187.7% | ||
| Q1 24 | — | -211.1% |
| Q4 25 | -295.3% | -231.9% | ||
| Q3 25 | -307.1% | -82.0% | ||
| Q2 25 | 2903.9% | -97.7% | ||
| Q1 25 | — | -268.4% | ||
| Q4 24 | — | -168.5% | ||
| Q3 24 | — | -265.3% | ||
| Q2 24 | -125.5% | 9.0% | ||
| Q1 24 | — | -281.2% |
| Q4 25 | $-0.34 | $-0.87 | ||
| Q3 25 | $-0.31 | $-0.65 | ||
| Q2 25 | $2.57 | $-0.94 | ||
| Q1 25 | — | $-1.87 | ||
| Q4 24 | — | $7.06 | ||
| Q3 24 | — | $-35.52 | ||
| Q2 24 | $-0.11 | $1.65 | ||
| Q1 24 | — | $-55.51 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $172.1M | $39.0M |
| Total DebtLower is stronger | — | $31.0M |
| Stockholders' EquityBook value | $61.0M | $38.2M |
| Total Assets | $258.3M | $105.3M |
| Debt / EquityLower = less leverage | — | 0.81× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $172.1M | $39.0M | ||
| Q3 25 | $191.7M | $11.8M | ||
| Q2 25 | $237.6M | $854.0K | ||
| Q1 25 | — | $3.9M | ||
| Q4 24 | — | $1.2M | ||
| Q3 24 | — | $1.6M | ||
| Q2 24 | $159.2M | $3.2M | ||
| Q1 24 | — | $10.9M |
| Q4 25 | — | $31.0M | ||
| Q3 25 | — | $23.0M | ||
| Q2 25 | — | $22.5M | ||
| Q1 25 | — | $21.7M | ||
| Q4 24 | — | $5.7M | ||
| Q3 24 | — | $32.3M | ||
| Q2 24 | — | $33.5M | ||
| Q1 24 | — | $44.0M |
| Q4 25 | $61.0M | $38.2M | ||
| Q3 25 | $87.8M | $29.9M | ||
| Q2 25 | $119.8M | $21.4M | ||
| Q1 25 | — | $32.8M | ||
| Q4 24 | — | $39.7M | ||
| Q3 24 | — | $34.4M | ||
| Q2 24 | $-84.1M | $52.1M | ||
| Q1 24 | — | $45.5M |
| Q4 25 | $258.3M | $105.3M | ||
| Q3 25 | $516.5M | $93.7M | ||
| Q2 25 | $439.5M | $78.4M | ||
| Q1 25 | — | $91.3M | ||
| Q4 24 | — | $89.2M | ||
| Q3 24 | — | $110.8M | ||
| Q2 24 | $674.9M | $116.7M | ||
| Q1 24 | — | $136.1M |
| Q4 25 | — | 0.81× | ||
| Q3 25 | — | 0.77× | ||
| Q2 25 | — | 1.05× | ||
| Q1 25 | — | 0.66× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.94× | ||
| Q2 24 | — | 0.64× | ||
| Q1 24 | — | 0.97× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-19.7M | $-7.7M |
| Free Cash FlowOCF − Capex | — | $-8.3M |
| FCF MarginFCF / Revenue | — | -88.3% |
| Capex IntensityCapex / Revenue | — | 6.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-19.7M | $-7.7M | ||
| Q3 25 | $-46.3M | $-6.0M | ||
| Q2 25 | $-46.6M | $-1.2M | ||
| Q1 25 | — | $-12.3M | ||
| Q4 24 | — | $-2.2M | ||
| Q3 24 | — | $-2.0M | ||
| Q2 24 | $59.7M | $-8.0M | ||
| Q1 24 | — | $-20.5M |
| Q4 25 | — | $-8.3M | ||
| Q3 25 | — | $-6.3M | ||
| Q2 25 | — | $-3.0M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-2.2M | ||
| Q3 24 | — | $-2.0M | ||
| Q2 24 | — | $-8.0M | ||
| Q1 24 | — | $-20.5M |
| Q4 25 | — | -88.3% | ||
| Q3 25 | — | -46.5% | ||
| Q2 25 | — | -22.2% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -17.7% | ||
| Q3 24 | — | -24.2% | ||
| Q2 24 | — | -77.1% | ||
| Q1 24 | — | -209.8% |
| Q4 25 | — | 6.4% | ||
| Q3 25 | — | 2.3% | ||
| Q2 25 | — | 13.3% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | — | 0.2% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -0.16× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -8.52× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CHRS
| Toripalimab | $12.4M | 97% |
| Other | $388.0K | 3% |
VELO
Segment breakdown not available.
